October 14, 2020 -- ERS Genomics, which has access to foundational CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, has signed an agreement with FASMAC of Japan.
Under the terms of the nonexclusive agreement, FASMAC acquires the rights to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it.
FASMAC was established in 2001 to provide food analysis and biotechnology products and services, including DNA and RNA synthesis products, DNA sequencing services, food testing services, and genetic analysis reagents and kits.